There are also preclinical studies of tucidinostat in combination with targeted therapies for NSCLC to reverse resistance to drugs that include epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) icotinib (Zhang N. et al., 2019) and the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) inhibitor crizotinib (Ding et al., 2020). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.